UPB
Upstream Bio, Inc.
$8.37
-0.09
(-1.06%)
Mkt Cap
455.50M
Volume
255,445
52W Range
7.25-33.68
Sector
Healthcare
Beta
1.29
EPS (TTM)
-2.91
P/E Ratio
-10.19
Revenue (TTM)
3.32M
Rev Growth (5Y)
+33.0%
EPS Growth (5Y)
N/A
Company Description
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | 2.85M | 2.37M | 2.38M | 1.21M |
| Net Income | (143.44M) | (62.81M) | (20.54M) | (23.87M) |
| EPS | -2.66 | -1.49 | -1.05 | -0.66 |
| Free Cash Flow | (133.28M) | (59.68M) | (38.07M) | (19.10M) |
| FCF / Share | -2.47 | -1.16 | -1.05 | -0.53 |
| Operating CF | (133.28M) | (59.17M) | (37.93M) | (19.02M) |
| Total Assets | 353.77M | 481.72M | 117.20M | 18.48M |
| Total Debt | 1.27M | 1.83M | 45,000 | 94,000 |
| Cash & Equiv | 101.58M | 325.89M | 25.83M | 17.05M |
| Book Value | 339.77M | 469.85M | (123.13M) | (106.16M) |
| Return on Equity | -0.42 | -0.13 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.03M | 668,000 | 683,000 | 937,000 | 566,000 | 613,000 | 607,000 | 510,000 | 640,000 | 450,000 | 621,000 |
| Net Income | (40.59M) | (42.46M) | (33.75M) | (39.97M) | (27.27M) | (21.24M) | (15.99M) | (14.68M) | (10.89M) | (11.83M) | (3.10M) |
| EPS | -0.75 | -0.79 | -0.63 | -0.74 | -0.51 | -0.41 | -0.41 | -0.38 | -0.27 | -0.41 | -0.17 |
| Free Cash Flow | (47.85M) | (30.68M) | (22.19M) | (39.29M) | (41.16M) | (19.80M) | (14.29M) | (8.04M) | (17.56M) | (16.11M) | (4.82M) |
| FCF / Share | -0.88 | -0.57 | -0.41 | -0.73 | -0.77 | -0.39 | -0.28 | -0.16 | -0.34 | -0.44 | -0.13 |
| Operating CF | (47.85M) | (30.63M) | (22.24M) | (39.24M) | (41.16M) | (19.61M) | (13.96M) | (8.04M) | (17.56M) | (16.11M) | (4.82M) |
| Total Assets | 318.05M | 353.77M | 391.19M | 420.52M | 456.17M | 481.72M | 232.70M | 244.51M | 0 | 117.20M | N/A |
| Total Debt | 1.11M | 1.27M | 1.42M | 1.56M | 1.70M | 1.83M | 1.94M | 0 | 0 | 45,000 | N/A |
| Cash & Equiv | 96.72M | 101.58M | 72.16M | 45.46M | 71.31M | 325.89M | 32.95M | 47.34M | 0 | 25.83M | N/A |
| Book Value | 304.00M | 339.77M | 378.58M | 408.74M | 445.61M | 469.85M | (160.31M) | (146.61M) | 107.81M | (123.13M) | N/A |
| Return on Equity | -0.13 | -0.12 | -0.09 | -0.10 | -0.06 | -0.05 | N/A | N/A | -0.10 | N/A | N/A |
UPB News
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights
Upstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International Conference
Here Are Friday’s Top Wall Street Analyst Research Calls: Brown-Forman, Chord Energy, Emerson Electric, FuboTV, Genmab, Honeywell, Knight-Swift, Wix.Com, and More
Upstream Bio Lead Drug Pivotal Trial Plan Follows Strong Phase 2 Data
Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results
Upstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026
Upstream Bio to Participate in Upcoming March Investor Conferences